Rebamipide and Pantoprazole Combination in NSAIDs-Gastropathy Treatment  

作　　者：Maher Mbarki Helen Sklyarova Krystyna Aksentiychuk1 Natalia Kharchenko Eugene Sklyarov 

机构地区：[1]Department of Therapy No. 1 and Medical Diagnostics, Lviv National Medical University Named After Danylo Halytsky, Lviv79010, Ukraine [2]Department of Gastroenterology, Dietology and Endoscopy, Shupyk National Medical Academy of Postgraduate Education, Kyiv04112, Ukraine

出　　处：《Journal of Pharmacy and Pharmacology》2017年第3期153-157,共5页药剂与药理学（英文版）

摘　　要：The objective of this study was to investigate the pantoprazole and rebamipide efficiency on NSAIDs （nonsteroidal anti-inflammatory drugs）-gastropathy restoring and healing in patients with coronary heart disease, stable angina, who have been taking aspirin for a long time period. The study included three groups of patients according to the treatment they have got： ASA （acetylsalicylic acid） in the first group; ASA and pantoprazole in the second; ASA, pantoprazole and rebamipide in the third one. To obtain the results, endoscopic method and proinflammatory cytokines LTB4 and protective prostaglandin E2 determination in the blood were used. The research demonstrated no ulcer effects in the group of patients who were treated by rebamipide, and significantly fewer gastroduodenal erosions, in comparison to the group, where treatment contained ASA and pantoprazole. The LTB4 （leukotriene B4） level decreased in pantoprazole and rebamipide treatment groups, but the PGE2 （prostaglandin E2） level increased only after rebamipide therapy. Therefore, rebamipide should be included to the therapy for the better NSAIDs-gastropathy treatment, in reason of its good reparative and gastroprotective properties.

关 键 词：NSAIDS acetylsalicylic acid PANTOPRAZOLE REBAMIPIDE GASTROPATHY LTB4 PGE2. 

分 类 号：S852.4[农业科学—基础兽医学] TQ463.4[农业科学—兽医学]